



fresh
insights

May 2020

Thromboembolism and Anticoagulant Therapy during the COVID-19 Pandemic: Interim Clinical Guidance from the Anticoagulation Forum

Journal of
**THROMBOSIS and
THROMBOLYSIS**
A Journal for Translation, Application and Therapeutics in Thrombosis and Vascular Science



[Download the
Guidance](#)

The Anticoagulation Forum is pleased to announce the publication of our new guidance: **Thrombosis and Anticoagulation Therapy during the COVID-19 Pandemic: Interim Clinical Guidance from the Anticoagulation Forum**, being published shortly with open access in the *Journal of Thrombosis and Thrombolysis*. The pre-print document is available in our [Anticoagulation Centers of Excellence Resource Center](#).

This guidance document addresses key issues pertaining to prevention or treatment of thrombotic events in hospitalized patients with COVID-19, with the overarching purpose of striking a balance between risks and benefits of anticoagulation therapies. Additionally, it covers in-hospital and post-discharge venous thromboembolism (VTE) prevention, treatment of suspected but unconfirmed VTE, laboratory monitoring of COVID-19, associated anticoagulant therapies, and essential elements for optimized transitions of care specific to patients with COVID-19. Lastly the guidance also addresses key strategies to minimize COVID-19 exposure risk for patients taking chronic anticoagulant medications.

For additional information on this topic watch our last webinar
Thrombosis in the Hospitalized COVID Positive Patient
presented by the following Anticoagulation Forum experts.

- Arthur Allen, PharmD
- Geoffrey Barnes, MD
- Allison Burnett, PharmD
- Mark Crowther, MD
- Adam Cuker, MD
- Bill Dager, PharmD
- Steve Deitelzweig, MD
- David Garcia, MD
- Tracy Minichiello, MD

[Watch Now](#)

[Download the Slides](#)

COVID-19 Hypercoagulability
McMaster University Chair's Medical Grand Rounds
Thursday | May 14, 2020 | 8:00 AM ET

AC Forum is pleased present this webinar along with McMaster University. Dr. Ted Warkentin will cover the following timely discussion points:

- Describe the laboratory and clinical features of COVID-19 hypercoagulability
- What is the significance of fibrin d-dimer elevation in COVID-19 infection?
- Compare and contrast COVID-19 hypercoagulability with other hypercoagulable disorders (HIT, sepsis)
- Discuss implications of COVID-19 hypercoagulability re: thrombosis prevention/treatment

Register Now!

Speaker:

Ted Warkentin, MD, BSc(Med), FRCPC, FACP, FRCP (Edin)
Transfusion Medical Director, Hamilton General Hospital
Professor, McMaster University

Moderators:

Mark Crowther, MD MSc, FRCPC, FRSC
Chair, Department of Medicine, McMaster University

Scott Kaatz, DO, MSc, FACP, SFHM
Senior Hospitalist, Henry Ford Hospital
Clinical Professor, Medicine at Wayne State University

Anticoagulation Forum Position Statement Advocating for Resources & Alternative Options for High-Risk Patients during the Public Health Emergency caused by COVID-19 (Updated May 2020)

Centers for Medicare & Medicaid Services (CMS) recently published an Interim final rule with comment period (CMS-1744-IFC) stating it would not enforce the 3-month minimum warfarin duration clinical indication for home INR testing eligibility for the duration of the COVID-19 public health emergency. The AC Forum has submitted a position statement to CMS and encourages all members to participate during this comment period which ends **June 1, 2020**.

The Anticoagulation Forum advocates to allow patients to safely remain in their homes yet also maintain the safety and efficacy of their anticoagulant medication. For patients ineligible for alternative anticoagulant therapies, we advocate for the option to provide INR testing device and supplies shipped directly to the patient with a health care provider performing the PST training via virtual visits and billing codes G0248 and G0249.

ACF Position Statement

If you are interested in participating, your comment must be received
no later than 5 p.m. on June 1, 2020
referencing file code (CMS-1744-IFC).

Submit comments to CMS

More information on the IFC can be found here:

- [regulations.gov](https://www.regulations.gov)
- [CMS-1744-IFC Document](#)

Our curated literature resource has been updated!



Special thanks to Dr. Bishoy Ragheb who updates our literature search by topic. In the last update on April 27, 2020 we have **98** with (32 COVID-19) new articles organized by topic.

[Download the latest updates](#)

Thank You to Our Newsletter Sponsors



Bristol-Myers Squibb

